Abstract. Aims of this chapter on the role of toxicoproteomics in assessing organ-specific toxicity are to define the field of toxicoproteomics, describe its development among global technologies, and show potential uses in experimental toxicological research, preclinical testing and mechanistic biological research. Disciplines within proteomics deployed in preclinical research are described as Tier I analysis, involving global protein mapping and protein profiling for differential expression, and Tier II proteomic analysis, including global methods for description of function, structure, interactions and post-translational modification of proteins. Proteomic platforms used in toxicoproteomics research are briefly reviewed. Preclinical toxicoproteomic studies with model liver and kidney toxicants are critically assessed for their contributions toward understanding pathophysiology and in biomarker discovery. Toxicoproteomics research conducted in other organs and tissues are briefly discussed as well. The final section suggests several key developments involving new approaches and research focus areas for the field of toxicoproteomics as a new tool for toxicological pathology.
Introduction
Toxicoproteomics applies global protein measurement technologies to toxicology testing and research. Aims of the field are the discovery of mechanisms governing key proteins in critical biological pathways creating adverse drug effects, development of biomarkers, and eventual prediction of toxicity based upon pharmacogenomic knowledge [1] [2] [3] [4] .
An increasing number of proteomic applications to many established scientific disciplines have generated great interest and enthusiasm in basic biology and medicine, as well as toxicology. There are well over 10 000 publications relating to some aspects or applications of proteomics in the biosciences. However, the numbers of published proteomic studies is quite limited in reporting primary data for drug-mediated adverse reactions and biochemical toxicities that lead to undesirable phenotypes [5] [6] [7] . Toxicoproteomics was initially developed under the auspices of toxicogenomics [8] and proteomics [9] , but it has emerged as its own discipline. Toxicoproteomics is defined by goals of furthering mechanistic understanding of how specific exposures alter protein expression, protein behavior and response to cause injury and disease, but has also been greatly influenced by a growing body of research focusing upon key organs such as liver and kidney. The field has been augmented by tools from proteomics, bioinformatics and other enabling high throughput technologies. Interestingly, it might be argued that the overt pursuit of defining biomarkers as a major objective in toxicoproteomics research may not be appropriate or right. Biomarkers should be a natural progression of excellence in research from elucidating toxic mechanisms or modes of chemical actions in response to acute exposure to toxicants or during the long-term development of diseases caused or influenced by these exposures. Compared with such an important mission, the identification of biomarkers might be or should be a comparatively smaller part of the whole picture of toxicoproteomics. However, as a motivating factor, biomarker and toxicity signature discovery is very high in the minds of those who use proteomics in toxicology [10, 11] . Major drivers in toxicoproteomics are the commercial need to discover markers associated with drug exposure, efficacy or toxicity in the pharmaceutical arena, and also the urgencies of environmental hazard evaluation for the protection of public health. Finally, an overarching principle among all discovery technologies is that eventual placement of protein changes within biochemical pathways and processes will result from a mechanistic understanding of larger biochemical systems and signaling networks. Systems biology has come to represent this wider integration of functional genomics disciplines such as transcriptomics, proteomics, interactomics and metabolomics among organisms [12, 13] .
Issues for toxicoproteomics and toxicogenomics in pharmaceutical data submission have been recently reviewed regarding non-clinical safety testing to regulatory agencies [14] . Several issues are still in development for data submission of genomics and proteomics studies to regulatory agencies. These would include data quality standards, wide differences in platforms and data formats, accepted criteria for data validation, relationships to traditional toxicological endpoints, added-value to established biochemical and molecular methods, animal-to-human extrapolation, mechanism of action, impact upon the NOAEL ("no observed adverse effect level"), early compared to adaptive or non-pharmacological responses, limits of bioinformatics algorithms, tools and available databases, and defined metrics of how and when genomic and proteomic data would influence regulatory decisions.
Toxicoproteomics and metabonomics have sometimes been called to task for their seemingly meager contributions to biomarker discovery compared to more well-established clinical chemistry and histopathology indicators. For example, a review of 13 toxicoproteomic and metabonomic studies with various nephrotoxic agents examined them for their respective abilities to determine specificity and sensitivity of renal toxicity. The review concluded that proteomics (and metabonomics) data compared very poorly with traditional methods of blood and urine chemistries and histopathology without significant improvements [15] . However, it is the potential for discovery and new insights into pathobiology and therapeutics that fuels interest in Omics technologies. In defense of these new fields, the same criticism could be levied upon pathology, histology and clinical chemistry for the many years and countless studies
